^
Association details:
| Biomarker: | PTEN expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Eligard (leuprolide acetate) (GnRH agonist) + Erleada (apalutamide) (Androgen receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).
Published date:
05/13/2020
Excerpt:
≤ypT2N0 associates with diagnostic biopsy positivity for the prespecified molecular signature (p <0.0001), PTEN expression (p: 0.004), absence of cribriform/ intraductal spread (p 0.002) but not with Gleason Score. On multivariate analysis only the prespecified biopsy signature associates with outcome (p 0.003).
DOI:
10.1200/JCO.2020.38.15_suppl.5504
Trial ID:
